BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 10717779)

  • 1. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
    Elomaa K; Lähteenmäki P
    Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
    Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
    Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ovulation by low-dose monophasic contraceptive containing gestodene.
    Thomas K; Vankrieken L
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 2):1404-10. PubMed ID: 2121037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanism of action of a new low-dosed combined oral contraceptive.
    Dericks-Tan JS; Schneider K; Taubert HD
    Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
    Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
    Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimeric inhibin serum values as markers of ovarian activity in pill-free intervals.
    Renier MA; Vereecken A; Van Herck E; Straetmans D; Ramaekers P; Vanderheyden J; Degezelle H; Buytaert P
    Contraception; 1998 Jan; 57(1):45-8. PubMed ID: 9554250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ovulation by a new low-dose monophasic contraceptive containing gestodene.
    Thomas KH; Vankrieken L
    Int J Fertil; 1989 Sep; 34 Suppl():10-21. PubMed ID: 2576249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory criteria for menopause in women using oral contraceptives.
    Creinin MD
    Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity.
    Sullivan H; Furniss H; Spona J; Elstein M
    Fertil Steril; 1999 Jul; 72(1):115-20. PubMed ID: 10428158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian follicles during oral contraceptive cycles: their potential for ovulation.
    Killick SR
    Fertil Steril; 1989 Oct; 52(4):580-2. PubMed ID: 2680616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulsatile luteinizing hormone secretion during the first and the fourth cycle on two different oral contraceptives containing gestodene.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):229-36. PubMed ID: 8212988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
    Landgren BM; Diczfalusy E
    Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.